Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02693990 · ClinicalTrials.gov registry record · NA
A Trial of Increased Dose Intensity Modulated Proton Therapy (IMPT) for High-Grade Meningiomas
A NA study of Brain Tumor and Meningioma, sponsored by Massachusetts General Hospital.
- Active
- Registry status
- NA
- Development phase
- 21
- Enrollment target
- 2
- Study locations
NCT02693990: Active NA study of Brain Tumor and Meningioma, sponsored by Massachusetts General Hospital.
NCT02693990 is a NA study of Brain Tumor and Meningioma that is active but no longer recruiting, run by Massachusetts General Hospital. The registered enrollment target is 21 participants, below the 281-participant average among 69 other Brain Tumor trials with a reported enrollment target (93% lower). The trial reports 2 study locations across 2 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02693990, a NA study of Brain Tumor and Meningioma, is active but no longer recruiting, sponsored by Massachusetts General Hospital.
- ACTIVE NOT RECRUITING
- Registry status
- NA
- Development phase
- 21 participants
- Enrollment target
- 2
- Study locations
Study Summary
This research study is studying radiation therapy as a possible treatment for meningioma or tumor on the lining of the brain. The study drug or intervention involved in this research study is Intensity Modulated Proton Therapy (IMPT)
Primary Outcome
Establish a safe increased-dose of post-operative IMPT with SIB in treating each of two meningioma cohorts: grade II (atypical) with subtotal resection and grade III (malignant) with gross total resection. Dose-limiting toxicity (DLT) using NCI CTC 4.0 will be assessed from the start of protocol treatment. The dose-seeking plan for each meningioma cohort will follow a modified 3+3 design with the starting and reduced doses for CTV and GTV.
Conditions Studied
Interventions
- RADIATION Intensity Modulated Proton Therapy (IMPT)
Study Locations (2)
Massachusetts
- Massachusetts General Hospital - Boston
Texas
- MD Anderson Cancer Center - Houston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 21 participants |
| Start Date | 2016-02 |
| Est. Completion | 2027-08 |
| Phase | NA |
What the registry record for NCT02693990 still lists
NCT02693990 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 21 participants, a relatively small participant target, below the 281-participant average among 69 other Brain Tumor trials with a reported enrollment target (93% lower).
The record links to 2 conditions, with Brain Tumor appearing as the primary indexed condition, and to 1 intervention - of which Intensity Modulated Proton Therapy (IMPT) is the first listed.
NCT02693990 reports a single indexed study location in Massachusetts, Texas.
Frequently Asked Questions
What is clinical trial NCT02693990 about?
NCT02693990 is a clinical study titled "A Trial of Increased Dose Intensity Modulated Proton Therapy (IMPT) for High-Grade Meningiomas". This research study is studying radiation therapy as a possible treatment for meningioma or tumor on the lining of the brain. The study drug or intervention involved in this research study is Intensity Modulated Proton Therapy (IMPT)
What is the current status of trial NCT02693990?
This trial is currently active not recruiting. It is a NA study. The enrollment target is 21 participants. The study started on 2016-02. Estimated completion is 2027-08.
What conditions does trial NCT02693990 study?
This clinical trial studies the following conditions: Brain Tumor, Meningioma.
What interventions are being tested in trial NCT02693990?
The interventions under investigation include: Intensity Modulated Proton Therapy (IMPT) (RADIATION).
Who is sponsoring clinical trial NCT02693990?
This trial is sponsored by Massachusetts General Hospital, which has 2,032 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02693990 being conducted?
This trial has 2 study locations across Massachusetts, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Brain Tumor
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT02693990's enrollment target sits among peer trials
21 56th of 69 higher than 14 of 69 other Brain Tumor trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Brain Tumor trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
LITT Followed by Hypofractionated RT for Newly Diagnosed Gliomas (GCC 20138)
RECRUITING · NA
-
Cognitive Training in the Virtual Reality Setting With Children Undergoing Radiotherapy for Brain Tumors
RECRUITING · NA
-
Extracellular Impact of Ultrasound-induced Blood-brain Barrier Disruption
RECRUITING · NA
-
Ommaya Reservoir Placement for Brain Tumor Biomarker Access
RECRUITING · NA
-
Mapping of Human Cognition
RECRUITING · NA
-
LITT Followed by Hypofractionated RT for Recurrent Gliomas
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02447874 · 21 participants · Phase 1
Arginine Therapy for the Treatment of Pain in Children With Sickle Cell Disease
- NCT03826992 · 21 participants · Phase 1
Venetoclax Combined With Vyxeos (CPX-351) for Participants With Relapsed or Refractory Acute Leukemia
- NCT04107077 · 21 participants · Phase 2
Phase II Study of the Effects of Laparoscopic Hyperthermic Intraperitoneal Chemotherapy (HIPEC) in Patients With Advanced Gastric Cancer
- NCT04158635 · 21 participants · Phase 1
Gemcitabine, Nab-Paclitaxel, and Bosentan for the Treatment of Unresectable Pancreatic Cancer
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia